PRAX News

Updated Monday, 11/9. The US IPO market remains relatively quiet following election week, with three biotechs and one SPAC scheduled to raise $340 million in the week ahead. Oncology biotech IN8bio (INAB) plans to raise $75 million at a $325 million market cap. IN8bio is focused on developing cancer therapies by employing allogeneic, autologous...read more

Nine IPOs and five SPACs went public this past week, and one IPO postponed. New filing activity continued to pump the breaks as we near the election, with just one new IPO filing. SPAC activity continued unabated however as nine submitted initial filings. The largest deal of the week, Array Technologies (ARRY) upsized and priced above the range to raise $1.0...read more

Praxis Precision Medicines, a Phase 2 biotech developing therapies for CNS disorders using genetic insights, raised $190 million by offering 10 million shares at $19, above the range of $17 to $18.  The company originally filed to offer 7.4 million shares at a range of $16 to $18, before increasing the proposed share offering and narrowing the range toward the high end in...read more

Praxis Precision Medicines, a Phase 2 biotech developing therapies for CNS disorders using genetic insights, raised the proposed deal size for its upcoming IPO on Thursday. The Cambridge, MA-based company now plans to raise $175 million by offering 10 million shares at a price range of $17 to $18. The company had previously filed to offer 7.4 million shares at a range of $16 to...read more